Form 4: Phathom Pharmaceuticals COO Azmi Nabulsi Reports Stock Transactions

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, reports acquisition of restricted stock units and disposal of common stock.

Summary

• On May 31, 2024, Azmi Nabulsi, the Chief Operating Officer of Phathom Pharmaceuticals, reported transactions involving the company's stock.
• Nabulsi acquired 7,500 restricted stock units (RSUs) at a price of $0.
• These RSUs vest in three equal installments on the anniversaries of December 18, 2023.
• Each RSU represents the right to receive one share of Phathom Pharmaceuticals common stock.
• Nabulsi also disposed of 3,578.93 shares of common stock held indirectly through a 401(k).
• Following these transactions, Nabulsi directly owns 249,567 shares and indirectly owns 785,700 shares through a trust.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, like the COO, transacts in their company's stock. It provides transparency to the market regarding the trading activities of key personnel.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding insider trading activity.
• The vesting of RSUs may incentivize the COO to continue service with the company.

Key Dates